The Antisense Oligonucleotides market is driven by growing demand for personalized medicine and treatment efficiencies. Antisense oligonucleotides, also known as ASOs, are short single strands of synthetic DNA or RNA that are used to inhibit gene expression through the process of RNase H-mediated degradation of target messenger RNA (mRNA). ASOs have advantages over small-molecule drugs and biologics as they can be designed to selectively target disease-causing genes without affecting the expression of other genes, representing a promising therapeutic approach for various genetic disorders.
The Global Antisense Oligonucleotides Market is estimated to be valued at US$ 3356.36 Mn in 2024 and is expected to exhibit a CAGR of 7.1% over the forecast period between 2024 to 2031.
Key Takeaways
Key players operating in the Antisense Oligonucleotides are SICK AG, Hitachi Ltd., Honeywell International Inc., Hyundai Elevator Co. Ltd., Nidec MCE, Toshiba Elevators and Building Systems, Thames Valley Controls, and Mitsubishi Electric. The growing demand for precision medicine and targeted therapeutics is a major factor driving the antisense oligonucleotides market. Conditions like cancer, infections diseases, cardiovascular diseases, and genetic disorders can now be treated more effectively with personalized antisense oligonucleotide therapeutics. Furthermore, the rising R&D investments by pharmaceutical companies and growing clinical pipeline of ASO drugs will also contribute to the market growth. Several companies are also expanding their antisense oligonucleotide drug portfolios and manufacturing operations globally to cater to the growing needs of the market.
Market key trends
One of the key trends in the Antisense Oligonucleotides Market Demand is the development of more potent and specific ASOs through advances in oligonucleotide chemistry and design. Second-generation ASOs with chemically modified backbones have enhanced potency, distribution properties, and pharmacokinetic profiles compared to first generation ASOs. Companies are developing ASOs with novel chemical modifications that can improve binding affinity to target mRNAs, stability against nucleases, tissue distribution, and other desirable pharmacological properties. This will enable development of highly effective ASO drugs for wide range of diseases.
Porter’s Analysis
Threat of new entrants: High capital requirements for manufacturing, equipment and launch of new products act as entry barriers.
Bargaining power of buyers: Large customer base with growing demand provides buyers with negotiating power against suppliers.
Bargaining power of suppliers: High dependency on raw material suppliers gives them stronghold on pricing and supply.
Threat of new substitutes: Ongoing research and emerging new technologies like RNAi could pose a threat of substitution.
Competitive rivalry: High competition among established players and new entrants intensifies price wars and forces continuous innovation.
Geographical Regions
North America remains the largest market for antisense oligonucleotides currently accounting for over 35% of total sales. Factors driving North American market includes higher healthcare spending, technological advancements and ongoing research activities by leading pharmaceutical companies in the region.
Asia Pacific region is emerging as the fastest growing regional market for antisense oligonucleotides. Growing population, rising healthcare investments from both public and private players and increasing focus on rare disease treatment in countries like China and India are boosting regional demand. With continued expansion of healthcare facilities in rural and tier 2 & 3 cities, Asia Pacific market is projected to register a double digit CAGR through 2031.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it